VBI Vaccines Inc/BC

CAMBRIDGE, MA · Biotech · Acquired

Therapeutic vaccines against infectious diseases and cancer

Claim this profile

Follows are private to you and power your alerts

Updated · vbivaccines.com

Sector
Biotech
Headquarters
CAMBRIDGE, MA
Latest Form D
Sep 2022
Total capital
$41.6M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$41.6M
8 Form D · last Sep 2022
49 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201020122014201620182020FEDERAL ↑EQUITY ↓Cumulative $41.6M2nd Form D$4.4M4th Form D$10.6M
201020122014201620182020FEDERAL ↑EQUITY ↓Cumulative $41.6M

Latest events

  • Private capital raisedForm D · SEC · 7th filing$4.7M
  • Private capital raisedForm D · SEC · 6th filing$1.1M
  • Private capital raisedForm D · SEC · 5th filing$7M
  • Private capital raisedForm D · SEC · 4th filing$10.6M
  • Private capital raisedForm D · SEC · 3rd filing$13.6M
  • Private capital raisedForm D · SEC · 2nd filing$4.4M
  • Private capital raisedForm D · SEC · 1st filing$275K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

1 record has no date or no amount, so it isn’t placed on the timeline.

Founders and team

From SEC Form D filings
  • ADAM LOGALDirectorNamed in SEC Form D filings
  • Athena E. KartsaklisExecutive OfficerNamed in SEC Form D filings
  • Avi MazaltovExecutive OfficerNamed in SEC Form D filings
  • Blaine McKeeDirectorNamed in SEC Form D filings
  • Christopher McNultyExecutive Officer, DirectorNamed in SEC Form D filings
  • CURT LOCKSHINExecutive OfficerNamed in SEC Form D filings
Show all 22 people
  • Damian BragaDirectorNamed in SEC Form D filings
  • DAVID ANDERSONExecutive OfficerNamed in SEC Form D filings
  • EGIDIO NASCIMENTOExecutive OfficerNamed in SEC Form D filings
  • Francisco Diaz-MitomaExecutive OfficerNamed in SEC Form D filings
  • JAMES MARTINExecutive OfficerNamed in SEC Form D filings
  • JEFF BAXTERExecutive Officer, DirectorNamed in SEC Form D filings
  • Jeffrey R. BaxterExecutive Officer, DirectorNamed in SEC Form D filings
  • Joanne CordeiroDirectorNamed in SEC Form D filings
  • MICHEL DE WILDEDirectorNamed in SEC Form D filings
  • Nell BeattieExecutive OfficerNamed in SEC Form D filings
  • SAM CHAWLADirectorNamed in SEC Form D filings
  • SCOTT REQUADTDirectorNamed in SEC Form D filings
  • Steve GillisDirectorNamed in SEC Form D filings
  • STEVEN GILLISDirectorNamed in SEC Form D filings
  • STEVEN RUBINDirectorNamed in SEC Form D filings
  • Tomer KarivDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .